Screener
Axsome Therapeutics AXSM Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total current liabilities | 439,211 | 378,836 |
| Contingent consideration, non-current | 73,730 | 77,540 |
| Loan payable, long-term | 117,850 | 117,746 |
| Operating lease liability, long-term | 22,385 | 23,182 |
| Finance lease liability, long-term | 5,844 | 4,206 |
| Total liabilities | 659,020 | 601,510 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding) | — | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's operating lease liabilities?
- Axsome Therapeutics (AXSM) reported operating lease liabilities of $22.39M in Q1 2026.
- How has Axsome Therapeutics's operating lease liabilities changed year-over-year?
- Axsome Therapeutics's operating lease liabilities decreased by 6.4% year-over-year, from $23.91M to $22.39M.
- What is the long-term trend for Axsome Therapeutics's operating lease liabilities?
- Over 3 years (2020 to 2025), Axsome Therapeutics's operating lease liabilities has grown at a 241.6% compound annual growth rate (CAGR), from $581.71K to $23.18M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Axsome Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude